- Home
- IMCR vs CMPR Comparison
IMCR vs CMPR Comparison
Compare IMCR & CMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- CMPR
- Stock Information
- Founded
- IMCR 2008
- CMPR 1994
- Country
- IMCR United Kingdom
- CMPR Ireland
- Employees
- IMCR N/A
- CMPR N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- CMPR Publishing
- Sector
- IMCR Health Care
- CMPR Consumer Discretionary
- Exchange
- IMCR Nasdaq
- CMPR Nasdaq
- Market Cap
- IMCR 1.8B
- CMPR 1.5B
- IPO Year
- IMCR 2021
- CMPR N/A
- Fundamental
- Price
- IMCR $37.20
- CMPR $62.81
- Analyst Decision
- IMCR Buy
- CMPR Strong Buy
- Analyst Count
- IMCR 9
- CMPR 2
- Target Price
- IMCR $57.00
- CMPR $72.00
- AVG Volume (30 Days)
- IMCR 284.7K
- CMPR 203.8K
- Earning Date
- IMCR 11-05-2025
- CMPR 10-29-2025
- Dividend Yield
- IMCR N/A
- CMPR N/A
- EPS Growth
- IMCR N/A
- CMPR N/A
- EPS
- IMCR N/A
- CMPR 0.58
- Revenue
- IMCR $356,145,000.00
- CMPR $3,403,079,000.00
- Revenue This Year
- IMCR $31.83
- CMPR $7.23
- Revenue Next Year
- IMCR $8.50
- CMPR $3.64
- P/E Ratio
- IMCR N/A
- CMPR $106.21
- Revenue Growth
- IMCR 26.78
- CMPR 3.38
- 52 Week Low
- IMCR $23.15
- CMPR $35.21
- 52 Week High
- IMCR $39.33
- CMPR $97.81
- Technical
- Relative Strength Index (RSI)
- IMCR 76.55
- CMPR 64.01
- Support Level
- IMCR $31.85
- CMPR $60.38
- Resistance Level
- IMCR $33.08
- CMPR $64.08
- Average True Range (ATR)
- IMCR 1.28
- CMPR 1.91
- MACD
- IMCR 0.50
- CMPR -0.37
- Stochastic Oscillator
- IMCR 100.00
- CMPR 72.96
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.